| common stock. The business address of each of ACA L.P., ACA GP, ACA, Mr. Atchinson and Mr. Gross is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. |
Our initial stockholders beneficially own 20% of the issued and outstanding shares of our common stock. Because of this ownership block, our initial stockholders may be able to effectively influence the outcome of all matters requiring approval by our stockholders, including the election of directors, amendments to our amended and restated certificate of incorporation and approval of significant corporate transactions, including approval of our initial business combination.
The holders of our founder shares have agreed (A) to vote any shares owned by them in favor of any proposed initial business combination and (B) not to redeem any shares in connection with a stockholder vote to approve a proposed initial business combination or in connection with a tender offer.
Our sponsor is deemed to be our “promoter” as such term is defined under the federal securities laws.
Item 13. Certain Relationships and Related Transactions, and Director Independence
On February 13, 2021, we issued an aggregate of 4,312,500 founder shares to Graf LLC for an aggregate purchase price of $25,000, or approximately $0.006 per share. On April 2, 2021, Graf LLC transferred all of its founder shares to our sponsor. On April 8, 2021, our sponsor transferred 20,000 founder shares to each of our independent directors, resulting in our sponsor holding 4,252,500 founder shares. The number of founder shares issued was determined based on the expectation that such founder shares would represent 20% of the outstanding shares upon completion of the IPO. The underwriters partially exercised their overallotment option on June 2, 2021, and forfeited the remaining option; and, as a result, an aggregate of 22,125 founder shares were forfeited, resulting in 4,290,375 founder shares outstanding. On July 14, 2021, the Sponsor transferred 20,000 founder shares to Alexandra Lebenthal in connection with her appointment to the Company’s board of directors.
Our sponsor purchased an aggregate of 4,433,333 private placement warrants at a price of $1.50 per warrant for an aggregate purchase price of $6,650,000 in a private placement that occurred simultaneously with the closing of the IPO. Simultaneously with the closing of the overallotment on June 2, 2021, the Company consummated the second closing of the private placement, resulting in the purchase of an aggregate of an additional 288,200 private placement warrants at $1.50 per private placement warrant, generating additional gross proceeds of approximately $432,000. Each private placement warrant entitles the holder to purchase one share of common stock at $11.50 per share. The private placement warrants (including the shares of common stock issuable upon exercise thereof) may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder.
On June 2, 2021, the underwriters partially exercised the over-allotment option and purchased an additional 2,161,500 units, generating gross proceeds of $21,615,000. A total of $171,615,000 of the net proceeds from the sale of the units, the over-allotment units and the private placement warrants was placed in the trust account.
As more fully discussed herein, if any of our officers or directors becomes unaware of an initial business combination opportunity that falls within the line of business of any entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity. Our officers and directors currently have certain relevant fiduciary duties or contractual obligations that may take priority over their duties to us.
No cash finder’s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us to our sponsor, officers and directors, or any affiliate of our sponsor or officers for services rendered, prior to, or for any services rendered in order to effectuate, the consummation of an initial business combination (regardless of the type of transaction that it is). However, as more fully discussed above, these individuals will be entitled to certain payments including, but not limited to, reimbursement for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Additionally, these individuals will be eligible to receive a transfer or reallocation of founder shares for any extraordinary services rendered in order to identify or effectuate the consummation of our initial business combination. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or their affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred by such persons in connection with activities on our behalf.